1. The plaintiff's claim is dismissed.

2. The costs of lawsuit shall be borne by the Plaintiff.

1. Basic facts

A. On June 17, 2008, the Plaintiff, an insurance company, entered into a non-dividend agreement with the Defendant (hereinafter “instant insurance contract”).

B. At the time of entering into the instant insurance contract, the Defendant subscribed to the instant special agreement Ⅳ E (the purchase price of KRW 20 million), and the main contents of the special agreement are as follows:

1. A loss (1) If the insured described in the insurance policy (insurance Policy) becomes diagnosed as cancer, thothothothothothotho, nethothothothothothothotho, nethothothothothothothotho, and sythothothothothothothothothothothothotho after the commencement date of

2.In this contract, the definitions and diagnosis confirmation of “Cham”, “other skin cancer”, and “Apam” mean diseases (referring to attached Table 5) classified as malicious organisms in the 5th Standard Disease Classification.

However, it excludes diseases falling under c44 and C73 among the terms of 'pregal disease', which are prescribed by the Ordinance of the Ministry of Construction and Transportation.

(3) In this Agreement, the term “Apyptam” means a disease corresponding to the classification number C73 (Attached Table 5) of the Apryptal Biological Classification Table.

(4) “암”, “기타피부암”, 및 “갑상샘암”의 진단 확정은 해부병리 또는 임상병리의 전문의사 자격증을 가진 자에 의하여 내려져야 하며, 이 진단은 조직(fixed tissue)검사, 미세침흡인검사(fine needle Aspiration Biopsy) 또는 혈액(hemic system)검사에 대한 현미경 소견을 기초로 하여야 합니다.

However, if it is not possible to conduct the above-mentioned pathological diagnosis, the clinical diagnosis of the above-mentioned celebite, “other skin cancer,” and “Aceleum cancer,” is of “Acele”, “other skin cancer,” and “Aceleum cancer.”